Union Science and Technology Minister Dr Jitendra Singh today said that the ‘Make in India’ initiative is playing a pivotal role in reducing the country’s dependency on imported Active Pharmaceutical Ingredients (APIs). Dr Singh, addressing the 6th CII Pharma and Life Sciences Summit in New Delhi, said that by strengthening the country’s domestic manufacturing, India is not only bolstering self-reliance but also ensuring critical healthcare supplies are readily available. Appreciating the pharma industry, Dr Singh said that India’s emergence as a hub for affordable, high-quality medicines is truly commendable. He added, that India now ranks 3rd in pharmaceutical production by volume and 14th by value. He added it must be focused on vaccine equity and technology transfer to enhance global vaccination efforts.
APIs are a crucial segment of the pharmaceutical industry. APIs are used to treat diseases in many areas such as oncology, cardiology, neurology, pulmonology, nephrology and others.
